Oculomucocutaneous syndrome

Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca (dry eyes) and the resulting scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]

Oculomucocutaneous syndrome
SpecialtyOphthalmology

References
  1. Wright, P (Mar 15, 1975). "Untoward effects associated with practolol administration: oculomucocutaneous syndrome". British Medical Journal. 1 (5958): 595–8. doi:10.1136/bmj.1.5958.595. PMC 1672788. PMID 1125623.
  2. Amos, HE; Lake, BG; Artis, J (Feb 18, 1978). "Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome". British Medical Journal. 1 (6110): 402–4. doi:10.1136/bmj.1.6110.402. PMC 1602979. PMID 146533.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.